JP2011503184A5 - - Google Patents

Download PDF

Info

Publication number
JP2011503184A5
JP2011503184A5 JP2010534042A JP2010534042A JP2011503184A5 JP 2011503184 A5 JP2011503184 A5 JP 2011503184A5 JP 2010534042 A JP2010534042 A JP 2010534042A JP 2010534042 A JP2010534042 A JP 2010534042A JP 2011503184 A5 JP2011503184 A5 JP 2011503184A5
Authority
JP
Japan
Prior art keywords
morpholino
protected
ring nitrogen
group
subunit monomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010534042A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011503184A (ja
JP5512533B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/012804 external-priority patent/WO2009064471A1/en
Publication of JP2011503184A publication Critical patent/JP2011503184A/ja
Publication of JP2011503184A5 publication Critical patent/JP2011503184A5/ja
Application granted granted Critical
Publication of JP5512533B2 publication Critical patent/JP5512533B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010534042A 2007-11-15 2008-11-14 モルホリノオリゴマーの合成方法 Active JP5512533B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US98819207P 2007-11-15 2007-11-15
US98820007P 2007-11-15 2007-11-15
US60/988,192 2007-11-15
US60/988,200 2007-11-15
PCT/US2008/012804 WO2009064471A1 (en) 2007-11-15 2008-11-14 Method of synthesis of morpholino oligomers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014063314A Division JP6178744B2 (ja) 2007-11-15 2014-03-26 モルホリノオリゴマーの合成方法

Publications (3)

Publication Number Publication Date
JP2011503184A JP2011503184A (ja) 2011-01-27
JP2011503184A5 true JP2011503184A5 (enExample) 2012-01-12
JP5512533B2 JP5512533B2 (ja) 2014-06-04

Family

ID=40293764

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010534042A Active JP5512533B2 (ja) 2007-11-15 2008-11-14 モルホリノオリゴマーの合成方法
JP2014063314A Active JP6178744B2 (ja) 2007-11-15 2014-03-26 モルホリノオリゴマーの合成方法
JP2016129716A Pending JP2016196494A (ja) 2007-11-15 2016-06-30 モルホリノオリゴマーの合成方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014063314A Active JP6178744B2 (ja) 2007-11-15 2014-03-26 モルホリノオリゴマーの合成方法
JP2016129716A Pending JP2016196494A (ja) 2007-11-15 2016-06-30 モルホリノオリゴマーの合成方法

Country Status (13)

Country Link
EP (1) EP2207779B1 (enExample)
JP (3) JP5512533B2 (enExample)
KR (1) KR101617472B1 (enExample)
CN (1) CN101861318A (enExample)
BR (1) BR122019021332A8 (enExample)
CA (2) CA2704261C (enExample)
DK (1) DK2207779T3 (enExample)
ES (1) ES2479393T3 (enExample)
HR (1) HRP20140646T1 (enExample)
IL (1) IL205776A0 (enExample)
MX (1) MX2010004955A (enExample)
RU (1) RU2606627C2 (enExample)
WO (1) WO2009064471A1 (enExample)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006086667A2 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
WO2010141511A2 (en) 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent rna interference, compositions and methods of use thereof
AU2010319314C1 (en) 2009-11-13 2016-09-01 Sarepta Therapeutics, Inc. Antisense antiviral compound and method for treating influenza viral infection
KR101981705B1 (ko) 2010-05-28 2019-05-24 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
WO2012031243A2 (en) 2010-09-03 2012-03-08 Avi Biopharma, Inc. dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
CN103154009B (zh) 2010-09-30 2015-06-10 日本新药株式会社 吗啉基核酸衍生物
AU2011326364B2 (en) 2010-11-12 2016-08-11 Sarepta Therapeutics, Inc. Antisense antibacterial compounds and methods
AU2011367230B2 (en) 2011-05-05 2017-08-10 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
CA2839593A1 (en) 2011-07-15 2013-01-24 Sarepta Therapeutics, Inc. Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
KR20140097398A (ko) 2011-11-18 2014-08-06 사렙타 쎄러퓨틱스, 인코퍼레이티드 기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트
WO2013082548A1 (en) 2011-11-30 2013-06-06 Sarepta Therapeutics, Inc. Oligonucleotides for treating expanded repeat diseases
ES2727481T3 (es) 2011-11-30 2019-10-16 Sarepta Therapeutics Inc Inclusión inducida de exón en atrofia muscular espinal
WO2013086444A2 (en) 2011-12-08 2013-06-13 Sarepta Therapeutics, Inc. Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna
CN108588073A (zh) 2011-12-28 2018-09-28 日本新药株式会社 反义核酸
US9920085B2 (en) 2012-03-20 2018-03-20 Sarepta Therapeutics, Inc. Boronic acid conjugates of oligonucleotide analogues
CN102702265A (zh) * 2012-05-14 2012-10-03 天津特安化学科技有限公司 一种固相合成磷酰二胺吗啉代寡核苷酸及方法
WO2014113540A1 (en) 2013-01-16 2014-07-24 Iowa State University Research Foundation, Inc. A deep intronic target for splicing correction on spinal muscular atrophy gene
JP6477464B2 (ja) * 2013-05-24 2019-03-06 味の素株式会社 モルフォリノオリゴヌクレオチドの製造方法
AU2014317961B2 (en) 2013-09-05 2020-07-30 Murdoch University Antisense-induced exon2 inclusion in acid alpha-glucosidase
EP3052512A4 (en) 2013-09-30 2017-02-22 Geron Corporation Phosphorodiamidate backbone linkage for oligonucleotides
BR112016020618B1 (pt) 2014-03-12 2023-04-04 Nippon Shinyaku Co., Ltd. Oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido
US9790495B2 (en) 2014-05-16 2017-10-17 Oregon State University Antisense antibacterial compounds and methods
CA2948568A1 (en) 2014-05-19 2015-11-26 David Greenberg Antisense antibacterial compounds and methods
PT3159409T (pt) 2014-06-17 2020-01-21 Nippon Shinyaku Co Ltd Ácido nucleico anti-sentido para utilização no tratamento da distrofia muscular de duchenne
JP6673211B2 (ja) 2014-10-14 2020-03-25 味の素株式会社 モルフォリノオリゴヌクレオチドの製造方法
WO2016108930A2 (en) 2014-12-31 2016-07-07 Geller Bruce L Antisense antibacterial compounds and methods
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
KR102644053B1 (ko) 2015-05-19 2024-03-06 사렙타 쎄러퓨틱스 인코퍼레이티드 펩티드 올리고뉴클레오티드 콘주게이트
US10849917B2 (en) 2015-06-01 2020-12-01 Sarepta Therapeutics, Inc. Antisense-induced exon exclusion in type VII collagen
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
RS62930B1 (sr) * 2015-08-05 2022-03-31 Eisai R&D Man Co Ltd Postupak za pripremu suštinski dijastereomerno čistog fosforodiamidatnog oligomera, fosforodiamidatni oligomer proizveden takvim postupkom i farmaceutska kompozicija koja sadrži fosforodiamidatni oligomer
MX2018002090A (es) 2015-08-24 2018-09-12 Halo Bio Rnai Therapeutics Inc Nanoparticulas de polinucleótido para modulación de expresión génica y sus usos.
HUE050061T2 (hu) 2015-09-15 2020-12-28 Nippon Shinyaku Co Ltd Antiszensz nukleinsav
WO2017047741A1 (ja) 2015-09-16 2017-03-23 日本新薬株式会社 筋萎縮症治療用アンチセンス核酸
JP2018530560A (ja) 2015-10-09 2018-10-18 サレプタ セラピューティクス， インコーポレイテッド デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法
EA201891419A1 (ru) 2015-12-15 2019-01-31 Сарепта Терапьютикс, Инк. Пептид-олигонуклеотидные конъюгаты
US11142764B2 (en) 2015-12-23 2021-10-12 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
AU2016379399B2 (en) 2015-12-23 2022-12-08 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
US11060089B2 (en) 2016-04-18 2021-07-13 Sarepta Therapeutics, Inc. Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
JP7042255B2 (ja) 2016-04-29 2022-03-25 サレプタ セラピューティクス， インコーポレイテッド ヒトｌｍｎａを標的にするオリゴヌクレオチド類縁体
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
MX384727B (es) 2016-05-24 2025-03-14 Sarepta Therapeutics Inc Procesos para preparar oligómeros
TWI737736B (zh) 2016-05-24 2021-09-01 美商薩羅塔治療公司 製備磷醯二胺嗎啉代寡聚物之方法
MX390906B (es) 2016-05-24 2025-03-21 Sarepta Therapeutics Inc Procesos para preparar oligómeros de morfolino fosforodiamidato.
US10947533B2 (en) 2016-05-24 2021-03-16 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
MA45158A (fr) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Composition pharmaceutique comprenant de l'éteplirsen
CA3024153A1 (en) * 2016-06-30 2017-11-30 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
AU2017330276B2 (en) * 2016-09-20 2022-01-20 The Regents Of The University Of Colorado, A Body Corporate Synthesis of backbone modified morpholino oligonucleotides and chimeras using phosphoramidite chemistry
ES3051834T3 (en) 2016-12-19 2025-12-30 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy
NZ755416A (en) 2016-12-19 2023-05-26 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy
PT4122497T (pt) 2016-12-19 2024-06-12 Sarepta Therapeutics Inc Conjugados oligoméricos de salto de exão para a distrofia muscular
ES2994451T3 (en) 2017-04-20 2025-01-24 Atyr Pharma Inc Compositions for treating lung inflammation
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
TWI812647B (zh) 2017-09-25 2023-08-21 美商薩羅塔治療公司 經由速流合成以製備磷醯二胺嗎啉代寡聚物之製程
US11555189B2 (en) 2017-10-18 2023-01-17 Sarepta Therapeutics, Inc. Antisense oligomer compounds
US11560401B2 (en) 2018-05-10 2023-01-24 Nippon Shinyaku Co., Ltd. Method for preparing oligonucleic acid compound
US10765760B2 (en) 2018-05-29 2020-09-08 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
EP4219717A3 (en) 2018-06-13 2023-12-20 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
JP7345466B2 (ja) 2018-06-26 2023-09-15 日本新薬株式会社 アンチセンスオリゴヌクレオチドを含有する組成物およびデュシェンヌ型筋ジストロフィーの治療へのその使用
TW202449155A (zh) 2018-07-27 2024-12-16 美商薩羅塔治療公司 用於肌肉萎縮症之外顯子跳躍寡聚物
BR112021011018A2 (pt) 2018-12-13 2021-08-31 Sarepta Therapeutics, Inc. Conjugados de oligômero para exon skipping para distrofia muscular
GB201821269D0 (en) 2018-12-28 2019-02-13 Nippon Shinyaku Co Ltd Myostatin signal inhibitor
WO2021025899A1 (en) 2019-08-02 2021-02-11 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer pharmaceutical compositions
EP4059943A4 (en) 2019-11-13 2024-01-31 Nippon Shinyaku Co., Ltd. METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND
EP4059944A4 (en) 2019-11-13 2024-04-10 Nippon Shinyaku Co., Ltd. METHOD FOR PREPARING AN OLIGONUCLICE ACID COMPOUND
EP4079329A4 (en) 2019-12-19 2024-04-17 Nippon Shinyaku Co., Ltd. ANTISENSE NUCLEIC ACID ENABLING EXON SKIPPING
IL294271A (en) 2019-12-26 2022-08-01 Nippon Shinyaku Co Ltd Antisense nucleic acid that induces skipping of exon 50
PE20230237A1 (es) 2020-02-28 2023-02-07 Nippon Shinyaku Co Ltd Acidos nucleicos antisentido que inducen la omision del exon 51
EP4182315A4 (en) * 2020-07-10 2024-07-03 Changzhou Syntheall Pharmaceuticals Co., Ltd. Processes for preparing oligonucleotides
EP4276104A3 (en) * 2021-03-19 2024-05-22 Bachem Holding AG Improved oligonucleotide synthesis suppressing depurination
CN117279926A (zh) 2021-04-28 2023-12-22 日本新药株式会社 低聚核酸化合物的制造方法
WO2022239863A1 (ja) 2021-05-13 2022-11-17 国立大学法人千葉大学 アンチセンスオリゴマー
AU2022279820A1 (en) 2021-05-28 2023-12-14 Sumitomo Pharma Co., Ltd. Antisense nucleic acid
JPWO2022270585A1 (enExample) 2021-06-23 2022-12-29
TW202308664A (zh) 2021-07-08 2023-03-01 日商日本新藥股份有限公司 腎毒性減輕劑
US20240316093A1 (en) 2021-07-08 2024-09-26 Nippon Shinyaku Co., Ltd. Nephrotoxicity reducing agent
TW202317147A (zh) 2021-07-08 2023-05-01 日商日本新藥股份有限公司 析出抑制劑
WO2023026994A1 (ja) 2021-08-21 2023-03-02 武田薬品工業株式会社 ヒトトランスフェリンレセプター結合ペプチド－薬物コンジュゲート
WO2023034515A2 (en) 2021-09-03 2023-03-09 Sarepta Therapeutics, Inc. Delivery of anitsense oligomers by mirror image peptides
US20240425864A1 (en) 2021-09-30 2024-12-26 Sarepta Therapeutics, Inc. Antisense oligonucleotides having one or more abasic units
WO2023070086A1 (en) 2021-10-22 2023-04-27 Sarepta Therapeutics, Inc. Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases
KR20240129006A (ko) 2021-12-27 2024-08-27 니뽄 신야쿠 가부시키가이샤 올리고 핵산 화합물의 제조 방법
KR20240155905A (ko) * 2022-03-01 2024-10-29 에자이 알앤드디 매니지먼트 가부시키가이샤 비스-보호된 활성화된 구아닌 단량체
EP4590311A2 (en) 2022-09-21 2025-07-30 Sarepta Therapeutics, Inc. Dmd antisense oligonucleotide-mediated exon skipping efficiency
EP4702144A1 (en) 2023-04-27 2026-03-04 Sarepta Therapeutics, Inc. Antisense oligomers for treatment of chronic kidney disease
JP2026526969A (ja) 2023-08-02 2026-08-10 サレプタ セラピューティクス， インコーポレイテッド アンチセンスオリゴマー送達のための非標準細胞透過性ペプチド
WO2025085810A2 (en) 2023-10-18 2025-04-24 Sarepta Therapeutics, Inc. Antisense oligomers for treatment of centronuclear myopathies
CN117586307B (zh) * 2024-01-19 2024-04-16 凯莱英生命科学技术(天津)有限公司 Pmo鸟苷单体的合成方法
CN122145519A (zh) * 2026-05-09 2026-06-05 中肽生化有限公司 磷酰二胺吗啉代寡核苷酸的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH577464A5 (enExample) * 1972-09-22 1976-07-15 Ciba Geigy Ag
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
ATE312834T1 (de) * 1989-12-20 2005-12-15 Avi Biopharma Inc Ungeladene, auf morpholin basierende polymere mit chiralen, phosphor enthaltenden brücken zwischen den untereinheiten
WO1991018898A1 (en) * 1990-06-01 1991-12-12 Nippon Shinyaku Co., Ltd. Nucleic acid homolog
US5510476A (en) 1994-07-07 1996-04-23 Isis Pharmaceuticals, Inc. Carbocation scavenging during oligonucleotide synthesis
UA48150C2 (uk) * 1994-11-02 2002-08-15 Ай-Сі-Ен Фармасьютикалз Похідні амінокислот або аміноспиртів, олігонуклеотид
US7790694B2 (en) * 2005-07-13 2010-09-07 Avi Biopharma Inc. Antisense antibacterial method and compound
LT2735568T (lt) * 2006-05-10 2017-11-27 Sarepta Therapeutics, Inc. Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų

Similar Documents

Publication Publication Date Title
RU2010123958A (ru) Способ синтеза морфолиновых олигомеров
JP4675318B2 (ja) Ｎ−アリールカルバミン酸エステルとハロ−ヘテロアリールとを反応させることによるｎ−ヘテロアリール−ｎ−アリール−アミンの調製のためのプロセスおよび類似のプロセス
JP4642860B2 (ja) フルオロアルキルスルホンの光酸発生部が置換された新規の単量体およびその重合体
AU2018200461B2 (en) Process methods for phosphatidylinositol 3-kinase inhibitors
EP3279181B1 (en) Method for producing a mixture of a polymerizable compound
JP2006517235A5 (enExample)
CN104520293A (zh) 抗病毒化合物的合成
JP2008528445A5 (enExample)
BR122017005939B1 (pt) Processo para a fabricação de derivados de sulfamida pirimidina
Aizpurua et al. “Click” synthesis of nonsymmetrical bis (1, 2, 3-triazoles)
Li et al. Rhodium (iii)-catalyzed aromatic C–H cyanation with dimethylmalononitrile as a cyanating agent
TW202216692A (zh) 新型Rho相關蛋白激酶抑制劑的製備方法和此製備方法中的中間體
CN116783160A (zh) 化合物库
JP2011527330A (ja) スニチニブリンゴ酸塩の結晶形の調製方法
TW201132630A (en) Imidazole derivatives
TWI225856B (en) Amide compounds
JP6112659B2 (ja) スルホニルアジド誘導体およびアシルスルホンアミド誘導体の製造方法並びにそれらの利用。
CN109963841A (zh) 4-((6-(2-(2,4-二氟苯基)-1,1-二氟-2-羟基-3-(5-巯基-1h-1,2,4-三唑-1-基)丙基)吡啶-3-基)氧基)苄腈及制备方法
US8722916B2 (en) Cyclopropyl MIDA boronate
DK3044204T3 (en) PHOTOLABLE LINKS FOR PHASE PHYSICAL SYNTHESIS OF HYDRAZIDES AND PYRANOPYRAZOLES
CN113024470A (zh) 一种4-全氟烷基取代嘧啶化合物及其制备方法与应用
JP2023065526A (ja) 酸性官能基のアルキル化方法
JP2017504658A5 (enExample)
CN116903489A (zh) 三联苯类化合物、其制备方法及其应用
CN101190927B (zh) 9-[2-(膦酰甲氧)乙基]腺嘌呤单特戊酰氧甲酯的制备方法